0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%
Abcam PLC (LON: ABC) – Consistent with its five-year plan to generate profitable growth.
Abcam Plc is an FTSE AIM All-Share listed multinational life sciences company founded in 1998 and headquartered in Cambridge, the United Kingdom. It produces and markets protein research agents and tools to assist life science researchers and clinical communities. ABC’s products include a diverse range of antibodies and protein research tools used by researchers critical for drug discovery and diagnostics. The key clients of ABC are researchers and scientists in academic institutions, pharmaceutical & biotechnology companies, research institutes and diagnostic companies. Abcam sells its products in Europe, Japan, China, the United States, Africa, the Middle East, and the Rest of Asia Pacific. Presently, the Company is serving more than 750,000 customers all around the globe.
On 13 September 2021, Abcam would announce its H2 FY2021 results.
Recent trend of dividend payments
(Data Source: LSE Website, Research done by Kalkine Group)
The chart above demonstrates the consistent dividend payment done by ABC from FY2017 to FY2020. The last dividend of FY2020, GBX 3.55 per share, was paid on 17 April 2020 (interim dividend). It had an ex-dividend date of 19 March 2020.
Growth Prospects
Key Risks
Now we will analyse some key fundamental and shareholders statistics of Abcam PLC.
Recent Development
Opening of new US facility in Boston, MA: On 13 July 2021, the Company announced the opening of a new site in Boston, the US, for supporting its research and development, manufacturing and commercial activities.
H2 FY2021 Pre-Close Trading Update (released on 1 July 2021)
H1 FY2021 Financial and Operational Highlights (for the six months ended 31 December 2020 as of 8 March 2021)
(Source: LSE Website)
Share Price Performance Analysis
(Source: Refinitiv, Research done by Kalkine Group)
On 22 July 2021, at 7:15 AM GMT, ABC’s shares were trading at GBX 1,297.00, up by 0.93% against the previous day closing price. Stock 52-week High and Low were GBX 1,740.00 and GBX 1,142.00, respectively.
The momentum indicator RSI (14-period) is trading at ~38.92 level and moving towards the oversold zone. Hence, there could be an uptick in the stock price in the near term.
In the last five years, ABC’s stock has delivered a decent positive return of ~72.02%. Also, it has outperformed the FTSE All-Share Pharmaceuticals and Biotechnology index with a return of around 27.37% and the FTSE AIM All-Share index with a return of about 64.23%.
Valuation Methodology: Price/Earnings Approach (NTM) (Illustrative)
Business Outlook Scenario
ABC has delivered a resilient performance in H2 FY2021 amid challenging conditions. The Company’s performance continues to meet the management’s expectations, with gradually increasing research activity. Continuous investments to capitalise on long-term opportunities and generate profitable growth provide further confidence. The Company could benefit from its differentiated value proposition, growing market trend and market share gains, its partnerships with diagnostic and biopharma organisations, its significant investments and its sustainability initiatives going forward. The management believes in investing to generate shareholder value. The Board expects that the policy changes and vaccination programmes would drive a return to full demand levels worldwide.
Considering the positive outlook of the global antibody market, the Company’s sustainability initiatives, the decent profitability, liquidity and leverage position of the business, and support from the valuation as done using the above method, we have given a “Speculative Buy” recommendation on Abcam Plc at the current price of GBX 1,297.00 (as of 22 July 2021 at 7:15 AM GMT), with lower-double digit upside potential based on 69.38x Price/NTM Earnings (approx.) on FY22E earnings per share (approx.).
*All forecasted figures and Peer information have been taken from Refinitiv.
*The dividend yield is subject to change as per the stock price movement.
*The reference data in this report has been partly sourced from Refinitiv.
*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.
Disclaimer
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.